New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
04:55 EDTBOTA, BOTA, BOTA, BOTA, IMGN, IMGN, IMGN, IMGN, ARRY, ARRY, ARRY, ARRY, OFIX, OFIX, OFIX, OFIX, CMN, CMN, CMN, CMN, MDCO, MDCO, MDCO, MDCO, TTHI, TTHI, TTHI, TTHI, INO, INO, INO, INO, CNAT, CNAT, CNAT, CNAT, Q, Q, Q, QJefferies to hold a conference
2014 Global Healthcare Conference to be held in New York on June 2-5.
News For BOTA;CNAT;INO;TTHI;MDCO;CMN;OFIX;ARRY;IMGN;Q From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 22, 2014
09:21 EDTMDCOThe Medicines Co. lowers 2014 revenue outlook to $720M-$735M
Subscribe for More Information
07:11 EDTMDCOMedicines Co. says Angiomax, Angiox revenue up 5% in first nine months
Subscribe for More Information
07:06 EDTMDCOThe Medicines Co. reports Q3 EPS (26c) , consensus (12c)
Subscribe for More Information
October 21, 2014
09:36 EDTCNATConatus initiated with a Buy at MLV & Co.
Subscribe for More Information
07:54 EDTIMGNLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information
06:10 EDTINOInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
09:48 EDTMDCOBrdiger Management reports 5.1% passive stake in The Medicines Co.
07:19 EDTIMGNIBC Life Sciences to hold a conference
Subscribe for More Information
07:12 EDTOFIXCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
October 15, 2014
11:27 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INO ATLS LOCO OPK INFY EUO FDO
October 13, 2014
12:25 EDTCNATConatus management to meet with Piper Jaffray
Subscribe for More Information
07:25 EDTMDCOEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
October 10, 2014
10:01 EDTQOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:53 EDTARRYArray drug has little evidence of being effective, says Summer Street
Subscribe for More Information
07:57 EDTQQuintiles upgraded at ISI Group
As previously reported, ISI Group upgraded Quintiles to Buy from Neutral. The firm sees further upside to shares driven by market product development growth, effective capital deployment, and an improving outlook for IHS. Price target is $61.
07:14 EDTMDCOThe Medicines Co's Q3 Angiomax estimate lowered at Credit Suisse
Subscribe for More Information
06:19 EDTQQuintiles upgraded to Buy from Neutral at ISI Group
Subscribe for More Information
October 9, 2014
16:57 EDTMDCOThe Medicines Co. announces journal publication of SOLO II phase 3 trial
The Medicines Company announced the publication of the results from the SOLO II phase 3 clinical trial of ORBACTIV, or oritavancin, for injection in the journal Clinical Infectious Diseases. ORBACTIV, is the first and only single dose intravenous antibiotic approved by FDA for the treatment of adults with Acute Bacterial Skin and Skin Structure Infections, or ABSSSI, caused or suspected to be caused by susceptible isolates of designated Gram-positive pathogens. The publication reported that a single, once only, 1200 mg intravenous dose of ORBACTIVTM was non-inferior to twice-daily intravenous dosing of vancomycin given for 7 to 10 days in patients with ABSSSI caused or suspected to be caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. A single 1200 mg IV dose of ORBACTIV results in efficacy in ABSSSIs that is comparable and statistically non-inferior to vancomycin administered intravenously for 7-10 days. ORBACTIV had a safety profile comparable to vancomycin when monitored for up to 60 days following a single dose, with similar intensity, onset and duration of AEs.
09:20 EDTARRYSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
October 8, 2014
10:03 EDTCNATConatus announces acceptance for AASLD abstract
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use